

# Mario Acunzo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4283526/publications.pdf>

Version: 2024-02-01

41  
papers

3,419  
citations

201674

27  
h-index

265206

42  
g-index

46  
all docs

46  
docs citations

46  
times ranked

6225  
citing authors

#	ARTICLE	IF	CITATIONS
1	Disparities in Lung Cancer: miRNA Isoform Characterization in Lung Adenocarcinoma. <i>Cancers</i> , 2022, 14, 773.	3.7	4
2	microRNAs as Novel Therapeutics in Cancer. <i>Cancers</i> , 2021, 13, 1526.	3.7	25
3	Non-Coding RNAs in Cancer Diagnosis and Therapy: Focus on Lung Cancer. <i>Cancers</i> , 2021, 13, 1372.	3.7	28
4	Detecting and Characterizing A-To-I microRNA Editing in Cancer. <i>Cancers</i> , 2021, 13, 1699.	3.7	17
5	MiREDiBase, a manually curated database of validated and putative editing events in microRNAs. <i>Scientific Data</i> , 2021, 8, 199.	5.3	18
6	Extracellular Vesicles in Lung Cancer Metastasis and Their Clinical Applications. <i>Cancers</i> , 2021, 13, 5633.	3.7	14
7	Non-Coding RNA Editing in Cancer Pathogenesis. <i>Cancers</i> , 2020, 12, 1845.	3.7	16
8	MiR-124a Regulates Extracellular Vesicle Release by Targeting GTPase Rabs in Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1454.	2.8	8
9	isoTar: Consensus Target Prediction with Enrichment Analysis for MicroRNAs Harboring Editing Sites and Other Variations. <i>Methods in Molecular Biology</i> , 2019, 1970, 211-235.	0.9	13
10	ncRNA Editing: Functional Characterization and Computational Resources. <i>Methods in Molecular Biology</i> , 2019, 1912, 133-174.	0.9	20
11	Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. <i>Cell Death and Differentiation</i> , 2019, 26, 1267-1282.	11.2	47
12	Editorial: Epitranscriptomics: The Novel RNA Frontier. <i>Frontiers in Bioengineering and Biotechnology</i> , 2018, 6, 191.	4.1	6
13	Tissue and exosomal miRNA editing in Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2018, 8, 10222.	3.3	38
14	RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21. <i>Molecular Therapy</i> , 2017, 25, 1544-1555.	8.2	115
15	Selective targeting of point-mutated KRAS through artificial microRNAs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E4203-E4212.	7.1	38
16	Small non-coding RNA and cancer. <i>Carcinogenesis</i> , 2017, 38, 485-491.	2.8	352
17	Extracellular Vesicle Biology in the Pathogenesis of Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1510-1518.	5.6	37
18	Novel Mechanisms of Regulation of miRNAs in CLL. <i>Trends in Cancer</i> , 2016, 2, 134-143.	7.4	30

#	ARTICLE	IF	CITATIONS
19	miR-579-3p controls melanoma progression and resistance to target therapy. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5005-13.	7.1	99
20	Extracellular miRNAs as biomarkers in cancer. Food and Chemical Toxicology, 2016, 98, 66-72.	3.6	31
21	microRNA editing in seed region aligns with cellular changes in hypoxic conditions. Nucleic Acids Research, 2016, 44, 6298-6308.	14.5	41
22	Downregulation of miR-15a and miR-16-1 at 13q14 in Chronic Lymphocytic Leukemia. Clinical Chemistry, 2016, 62, 655-656.	3.2	27
23	MAPK15 upregulation promotes cell proliferation and prevents DNA damage in male germ cell tumors. Oncotarget, 2016, 7, 20981-20998.	1.8	37
24	Post-transcriptional knowledge in pathway analysis increases the accuracy of phenotypes classification. Oncotarget, 2016, 7, 54572-54582.	1.8	43
25	MicroRNA in Cancer and Cachexiaâ€”A Mini-Review. Journal of Infectious Diseases, 2015, 212, S74-S77.	4.0	61
26	MicroRNA and cancer â€” A brief overview. Advances in Biological Regulation, 2015, 57, 1-9.	2.3	544
27	A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies. Oncotarget, 2015, 6, 20829-20839.	1.8	89
28	MicroRNA Profiles Discriminate among Colon Cancer Metastasis. PLoS ONE, 2014, 9, e96670.	2.5	99
29	miR-15b/16-2 Regulates Factors That Promote p53 Phosphorylation and Augments the DNA Damage Response following Radiation in the Lung. Journal of Biological Chemistry, 2014, 289, 26406-26416.	3.4	55
30	miR-Synth: a computational resource for the design of multi-site multi-target synthetic miRNAs. Nucleic Acids Research, 2014, 42, 5416-5425.	14.5	36
31	Translocation t(2;11) in CLL cells results in CXCR4/MAML2 fusion oncogene. Blood, 2014, 124, 259-262.	1.4	11
32	Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8573-8578.	7.1	105
33	Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RARÎ² and tumor regression. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9812-9817.	7.1	53
34	MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in nonâ€”small-cell lung cancer through BIM down-regulation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16570-16575.	7.1	150
35	miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood, 2011, 118, 3072-3079.	1.4	115
36	Mutated Î²-catenin evades a microRNA-dependent regulatory loop. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4840-4845.	7.1	48

#	ARTICLE	IF	CITATIONS
37	UCbase & miRfunc: a database of ultraconserved sequences and microRNA function. <i>Nucleic Acids Research</i> , 2009, 37, D41-D48.	14.5	38
38	PED is overexpressed and mediates TRAIL resistance in human non-small cell lung cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 2416-2426.	3.6	36
39	Akt Regulates Drug-Induced Cell Death through Bcl-w Downregulation. <i>PLoS ONE</i> , 2008, 3, e4070.	2.5	20
40	Activation of the Erk8 Mitogen-activated Protein (MAP) Kinase by RET/PTC3, a Constitutively Active Form of the RET Proto-oncogene. <i>Journal of Biological Chemistry</i> , 2006, 281, 10567-10576.	3.4	42
41	The Platelet-derived Growth Factor Controls c-myc Expression through a JNK- and AP-1-dependent Signaling Pathway. <i>Journal of Biological Chemistry</i> , 2003, 278, 50024-50030.	3.4	53